CFRX - CONTRAFECT Corp

0.22
0.220   100.000%

Share volume: 0
Last Updated: 11-08-2023

PREVIOUS CLOSE
CHG
CHG%
N/A
0.00
0.00%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Historical prices Events Documents Notes Dividends
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
-99.56%
1 Year
-99.50%
2 Year
-99.90%
Key data
Stock price
$0.22
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$0.00 - $0.03
52 WEEK CHANGE
-$99.50
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
10.705 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
N/A
AVERAGE 30 VOLUME 
N/A
Company detail
CEO: Roger J. Pomerantz
Region: US
Website: contrafect.com
Employees: 40
IPO year: 2025
Issue type: Common Stock
Market: XNAS
Industry:
Sector:

ContraFect Corporation discovers and develops therapeutic protein and antibody products. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia. CF-370, an investigational anti-bacterial therapeutic candidate, is in clinical trials to treat pseudomonas aeruginosa infections.

Recent news